SCHEMBL1854059

SCHEMBL1854059

CCOC(=O)C(=O)N(Cc1ccccc1)Cc1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KMT2A Q03164 4/20 0.55
TDP1 Q9NUW8 2/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 2/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 1/20 0.51
TP53 P04637 1/20 0.49
MEN1 O00255 2/20 0.48
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1853499 0.91 KMT2A (0.47) MAPTALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL7188228 0.87 MAPT (0.58) MAPTALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL1853180 0.87 LPAR1 (0.53) ALDH1A1SMN1; SMN2
SCHEMBL6423828 0.84 ALDH1A1 (0.48) ALDH1A1KMT2ATDP1SLC6A2SLC6A3
SCHEMBL6419997 0.83 L3MBTL1 (0.47) MAPTALDH1A1HPGDKMT2ATDP1
SCHEMBL11408485 0.82 KMT2A (0.76) MAPTALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL25374119 0.81 TSPO (0.51) MAPTALDH1A1KMT2ATDP1LMNA
SCHEMBL1855682 0.81 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KMT2ALMNAPOLB
SCHEMBL9837067 0.79 ALDH1A1 (0.70) MAPTALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL13469241 0.79 KMT2A (0.76) MAPTALDH1A1HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470102-B1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) MERCK SERONO SA (CH) 2011-05-25 EP disclosed
US-7592477-B2 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) LABORATOIRES SERONO SA (CH) 2009-09-22 US disclosed
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) APPLIED RESEARCH SYSTEMS ARS (NL) 2005-06-09 US disclosed
EP-1470102-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) Applied Research Systems ARS Holding N.V. (AN) 2004-10-27 EP disclosed
WO-2003064376-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) PTPRS, PTPA, PTPMT1 MAPT 4575/4885ALDH1A1 3733/4885HPGD 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.